Table 3.

Univariate logistic regression for the predicting of a pCR irrespective of study treatment

	pCR		Odds ratio	95% CI
	n	%
Menopausal status:
Premenopausal	12	11.3	2.17	0.73 to 6.41
Peri-/postmenopausal	5	5.6
Clinical tumour size:
≤ 4 cm	12	10.5	1.81	0.61 to 5.36
> 4 cm	5	6.1
Clinical nodal status:
Negative	14	14.3	5.28	1.47 to 19.00
Positive	3	3.1
Grading:
Grade I + II	2	2.2	0.13	0.03 to 0.61
Grade III	15	14.4
Clinical response after: 2 cycles ddAT
cCR/cPR	12	12.6	3.07	0.95 to 9.91
cNC/cPD	4	4.5
ER:
0 to 9%	15	17.4	11.41	2.53 to 51.41
10 to 100%	2	1.8
PgR:
0 to 9%	16	13.5	11.81	1.53 to 90.97
10 to 100%	1	1.3
Ki-67:
0 to 15%	3	4.0	0.32	0.09 to 1.15
16 to 100%	14	11.6
HER2:
0 to 2+	15	10.1	2.48	0.55 to 11.28
3+	2	4.3
p53:
1 to 50%	5	5.5	0.45	0.15 to 1.33
0 + 51 to 100%	12	11.4
bcl-2:
0 to 1+	16	12.9	10.52	1.36 to 81.09
2 to 3+	1	1.4

cCR, clinical complete response; cNC, clinical no change; cPD, clinical progressive disease; cPR, clinical partial response; ER, oestrogen receptor; HER2 human epidermal growth factor receptor 2; pCR, pathological complete remission; PgR, progesterone receptor.